DDInter1589 DDInter1628
A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Rifabutin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rifabutin {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rifabutin {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rifabutin {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Rifabutin {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) regulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rifabutin {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) CAMK1D
CAMK1D {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rifabutin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rifabutin {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is regulated by {v} (Gene) ZNF263
ZNF263 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rifabutin {u} (Compound) binds {v} (Gene) HSP90B1
HSP90B1 {u} (Gene) regulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Rifabutin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Rifabutin (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Rifabutin (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Rifabutin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) regulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Ruxolitinib (Compound)
Rifabutin (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is regulated by CAMK1D (Gene) and CAMK1D (Gene) is bound by Ruxolitinib (Compound)
Rifabutin (Compound) resembles Rifampicin (Compound) and Rifampicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Rifabutin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is regulated by ZNF263 (Gene) and ZNF263 (Gene) is upregulated by Ruxolitinib (Compound)
Rifabutin (Compound) resembles Rifapentine (Compound) and Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Rifabutin (Compound) binds HSP90B1 (Gene) and HSP90B1 (Gene) regulates TATDN2 (Gene) and TATDN2 (Gene) is upregulated by Ruxolitinib (Compound)